Charles Schwab Investment Management Inc. Decreases Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Charles Schwab Investment Management Inc. cut its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 10.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,611,996 shares of the company's stock after selling 184,842 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.73% of Hims & Hers Health worth $47,634,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of HIMS. Envestnet Asset Management Inc. lifted its stake in Hims & Hers Health by 139.2% in the 4th quarter. Envestnet Asset Management Inc. now owns 78,686 shares of the company's stock valued at $1,903,000 after buying an additional 45,791 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Hims & Hers Health in the 4th quarter valued at about $18,048,000. Summit Investment Advisors Inc. raised its holdings in Hims & Hers Health by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company's stock valued at $480,000 after acquiring an additional 628 shares during the last quarter. Barclays PLC raised its holdings in Hims & Hers Health by 48.3% in the 4th quarter. Barclays PLC now owns 457,246 shares of the company's stock valued at $11,056,000 after acquiring an additional 148,883 shares during the last quarter. Finally, Mariner LLC raised its holdings in Hims & Hers Health by 77.4% in the 4th quarter. Mariner LLC now owns 19,943 shares of the company's stock valued at $482,000 after acquiring an additional 8,699 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Down 2.2%

Shares of NYSE HIMS opened at $46.09 on Friday. The company has a 50 day simple moving average of $52.96 and a 200-day simple moving average of $45.63. The company has a market capitalization of $10.32 billion, a P/E ratio of 57.61, a P/E/G ratio of 2.91 and a beta of 2.08. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. Hims & Hers Health, Inc. has a 1 year low of $13.47 and a 1 year high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The firm had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%. The firm's quarterly revenue was up 72.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.06 EPS. On average, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Ratings Changes

HIMS has been the subject of a number of recent research reports. Truist Financial increased their price objective on shares of Hims & Hers Health from $45.00 to $48.00 and gave the company a "hold" rating in a report on Thursday, July 17th. Piper Sandler reiterated a "neutral" rating and issued a $39.00 price objective (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Bank of America increased their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a report on Tuesday, April 29th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Finally, Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Hims & Hers Health has an average rating of "Hold" and an average target price of $39.83.

Insider Activity at Hims & Hers Health

In related news, insider Patrick Harrison Carroll sold 60,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the completion of the transaction, the insider owned 169,940 shares of the company's stock, valued at approximately $9,105,385.20. This trade represents a 26.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Michael Chi sold 17,102 shares of the stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $59.75, for a total transaction of $1,021,844.50. Following the transaction, the insider directly owned 278,654 shares of the company's stock, valued at $16,649,576.50. The trade was a 5.78% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,273,034 shares of company stock worth $66,425,573. Company insiders own 13.71% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.